INHIBITORS OF THE MMRN2 INTERACTION WITH CLEC14A AND/OR CD93

Title:

INHIBITORS OF THE MMRN2 INTERACTION WITH CLEC14A AND/OR CD93

Document Type and Number:

WIPO Patent Application WO/2018/020222

Kind Code:

A3

Abstract:

The invention provides a portion of multimerin 2 (MMRN2) or a variant thereof, that inhibits the interaction between CLEC14A and MMRN2, in addition to a portion of MMRN2 or a variant thereof, that inhibits the interaction between CD93 and MMRN2. The invention provides compounds comprising said portions and either a cytotoxic moiety or a detectable moiety.

Inventors:

BICKNELL ROY (GB)
KHAN KABIR ALI (GB)

Application Number:

PCT/GB2017/052154

Publication Date:

March 01, 2018

Filing Date:

July 24, 2017

Export Citation:

Click for automatic bibliography generation Help

Assignee:

UNIV BIRMINGHAM (GB)

International Classes:

A61K39/00; C07K14/78; C07K14/47; C07K16/30

Domestic Patent References:

WO2016116760A2

2016-07-28

Other References:

DATABASE UniProt [online] 23 September 2008 (2008-09-23), "cDNA FLJ54049, highly similar to Multimerin-2", XP002775372, retrieved from EBI accession no. UNIPROT:B4DEW5 Database accession no. B4DEW5
P J NOY ET AL: "Blocking CLEC14A-MMRN2 binding inhibits sprouting angiogenesis and tumour growth", ONCOGENE, vol. 34, no. 47, 9 March 2015 (2015-03-09), pages 5821 - 5831, XP055268966, ISSN: 0950-9232, DOI: 10.1038/onc.2015.34
KABIR A KHAN ET AL: "CLEC14A - multimerin-2 interaction: a potential target for anti-angiogenic therapy", 16 July 2014 (2014-07-16), XP055268640, Retrieved from the Internet [retrieved on 20160426]
K A KHAN ET AL: "Multimerin-2 is a ligand for group 14 family C-type lectins CLEC14A, CD93 and CD248 spanning the endothelial pericyte interface", ONCOGENE, 3 July 2017 (2017-07-03), XP055417564, ISSN: 0950-9232, DOI: 10.1038/onc.2017.214